🇪🇺@EU_Commission informed @tevapharm of preliminary view it
➡️delayed competition to Copaxone (treatment of #MultipleSclerosis)
▪️artificially extended patent protection
▪️spread misleading information on competing product
➡️breached #EUAntitrust EU rules
🐦🔗: https://nitter.eu/arianna_podesta/status/1579425466146238470